Description

Cytokinetics: From Aficamten Trials to MYQORZO Launch—A High-Stakes Race in the HCM Market!

Cytokinetics, a biopharmaceutical company focused on muscle biology, marked a pivotal transition in 2025 with the FDA approval of MYQORZO for obstructive hypertrophic cardiomyopathy (HCM). This approval, coupled with similar approvals in China and a positive opinion from the European Medicines Agency, sets the stage for Cytokinetics’ entry into global commercialization. The company aims to provide a new treatment option for patients with obstructive HCM, a condition with significant unmet medical needs. The initial U.S. launch of MYQORZO has seen positive engagement from healthcare providers, evidenced by rapid REMS certification and prescription uptake. Cardiologists expressed enthusiasm for MYQORZO’s clinical profile, which includes flexible dosing and a lack of ejection fraction-related discontinuation—a notable differentiation from existing treatments. Cytokinetics aims to achieve a preferred new patient share of over 50% by 2026, leveraging MYQORZO’s clinical evidence, patient support services, and REMS differentiation to drive uptake. Outside the U.S.